Testing a return-to-work consultation for people treated for blood cancers
Tests an early work-return consultation in adults treated for leukemia, lymphoma or myeloma.
Plain-language title generated from the registry record
Registry title: RAT-HEMATO : Return to Work After Malignant Hemopathy
Key facts
- Where
- Angers, Brest, Caen, Cholet, Montivilliers, Morlaix, Rennes, Rouen, and Tours, FranceSee the 10 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT06262789, who can take part
Where in France
- Angers University HospitalAngers, FranceTaking people
- Brest University Hospital, Morvan SiteBrest, FranceTaking people
- Caen University HospitalCaen, FranceNot yet recruiting
- Service Hématologie, Cholet HospitalCholet, FranceNot yet recruiting
- Le Havre Hospital GroupMontivilliers, FranceNot yet recruiting
- Pays de Morlaix HospitalMorlaix, FranceNot yet recruiting
- Rennes University Hospital, Pontchaillou siteRennes, FranceNot yet recruiting
- Centre Henri BecquerelRouen, FranceTaking people
- Rouen University HospitalRouen, FranceNot yet recruiting
- Tours University Hospital, Bretonneau SiteTours, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Angers
- Trial code
- NCT06262789
- Record updated
- 4 September 2026
- Original description
Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their "pre-cancer life" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of "return-to-work self-efficacy" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.Read full original descriptionShow less
RAT-HEMATO : Return to Work After Malignant Hemopathy
Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their "pre-cancer life" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of "return-to-work self-efficacy" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.
Inclusion: Patient with hematological malignancy controlled after treatment; Induction/consolidation chemotherapy completed (excluding maintenance therapy); Patient aged 18 to 55; Patient having worked at least 6 months in the 2 years before diagnosis of hematological malignancy; Patient who has not yet returned to work since diagnosis of hematological malignancy; Signed informed consent form.
Exclusion: Patient with severe cognitive impairment at diagnosis, incompatible with the study; Patient choosing not to return to work; Patient not affiliated to a social security system; Patient with legal guardian or legal trustee; Patient not understanding French.